[Federal Register Volume 65, Number 146 (Friday, July 28, 2000)]
[Notices]
[Page 46487]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-19154]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Transcription Factor 
Decoy and Tumor Growth Inhibitor''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive world-wide license to U.S. Patent Applications 08/977,643, 
entitled: ``Transcription Factor Decoy and Tumor Growth Inhibitor'' 
plus, if available, corresponding foreign patent applications, to Genta 
Incorporated having a place of business in Lexington, MA. The patent 
rights in these inventions have been assigned to the United States of 
America and the contemplated license may be limited for use in the 
development and commercialization of diagnostic and therapeutic 
modalities to treat various diseases and inhibit tumor growth based on 
the use of cAMP Response Element-palindrome Oligonucleotide as a 
transcription factor decoy to regulate gene expression (i.e., gene 
transcription and translation).

DATES: Only written comments and/or applications for a license which 
are received by NIH on or before September 26, 2000 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: J. R. Dixon, Ph.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804. Telephone: (301) 496-7735 ext. 206; Facsimile: (301) 402-0220. A 
signed Confidentiality Agreement will be required to receive copies of 
the patent application.

SUPPLEMENTARY INFORMATION: The technology disclosed in USPA SN: 08/
977,643 patent application provides compositions and methods for the 
use of cAMP Response Element-palindrome oligonucleotide as a 
transcription factor decoy and an inhibitor of tumor growth. 
Specifically, the 08/977,643 application provides nucleic acid 
molecules that compete with cAMP Response Elements (``CRE'') for 
binding to transcription factors and a method for regulating gene 
transcription in target cells comprising: Providing one or more cAMP 
response element enhancer DNAs and one or more transcription factors 
that associate with the cAMP response element enhancer DNA; and 
exposing the target cells to the cAMP response element decoys under 
condition such that the cAMP response element decoys will compete with 
the cAMP response element enhancer DNA for binding to the one or more 
transcription factors.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    The field of use may be limited to the development and 
commercialization of diagnostic and therapeutics modalities to treat 
various diseases and inhibit tumor growth based on the use of cAMP 
Response Element-palindrome Oligonucleotide as a transcription factor 
decoy to regulate gene expression (i.e., gene transcription and 
translation).
    Applications for a license [i.e., completed ``Application for 
License to Public Health Service Inventions''] in the field of use in 
the development and commercialization of diagnostic and therapeutics 
modalities to treat various diseases and inhibit tumor growth based on 
the use of cAMP Response Element-palindrome Oligonucleotide as a 
transcription factor decoy to regulate gene expression (i.e., gene 
transcription and translation) filed in response to this notice will be 
treated as objections to the grant of the contemplated license. 
Comments and objections will not be made available for public 
inspection and, to the extent permitted by law, will not be subject to 
disclosure under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: July 19, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-19154 Filed 7-27-00; 8:45 am]
BILLING CODE 4140-01-P